Glaucoma News

No significant difference was seen in efficacy and safety of prostaglandin analogues when comparing original and generics, according to a systematic review published in Ophthalmology Glaucoma.

Regulatory bodies in Hong Kong and Argentina have approved Vyzulta for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, Nicox announced in a press release.

The ocular surface was found to change in patients treated with prostaglandin analogues, according to a literature review published in the Journal of Ophthalmology.

The use of OCT angiography in examining choroidal microvasculature may expedite glaucoma diagnoses in highly myopic eyes, according to findings published in the Journal of Glaucoma.

Santen plans to break into the U.S. glaucoma market in 2020 with the introduction of the DE-128 microshunt, according to a speaker at the 38th annual J.P. Morgan Healthcare Conference.

Calculating preliminary IOP using a smartphone-based tonometer yielded similar results compared with other tonometers, according to findings published in the British Journal of Ophthalmology.

ORLANDO, Fla. – Fixed combination therapies, new single agents with targeted mechanisms of action, laser surgery and future sustained release technologies may reduce the number of drops glaucoma patients need, Constance O. Okeke, MD, MSCE, said here at the Optometric Glaucoma Society meeting, held prior to the American Academy of Optometry meeting.

Vyzulta has been approved in Mexico for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, Nicox announced in a press release.

Keep up to date with the big news in ophthalmology.

A topical ocular formulation of AKB-9778 given as an adjunctive therapy reduced IOP and was well tolerated in patients with ocular hypertension or primary open-angle glaucoma, according to a press release from Aerpio Pharmaceuticals.